• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KVUE Shareholder Update: Johnson Fistel Encourages Kenvue Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline

By: Johnson Fistel, LLP via Business Wire
October 21, 2023 at 11:52 AM EDT

Johnson Fistel, LLP notifies investors of Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) a securities class action lawsuit has been filed. The lawsuit seeks to recover losses on behalf of investors who acquired securities pursuant to and/or traceable to the Company's May 2023 initial public offering ("IPO"). Investors have until December 8, 2023, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

If you would like to review the complaint and join the class action please follow the link below for more information:

https://www.johnsonfistel.com/investigations/kenvue-inc

There is no cost or obligation to you.

Complaint Allegations: The lawsuit alleges that, in the IPO documents, Defendants made false and/or misleading statements, as well as failed to disclose that: (i) Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine, which it knew or should have known; (ii) Kenvue did not discuss risks relating to the efficacy of phenylephrine in its IPO, the utility of which had been questioned since at least 2007; and (iii) while the Company disclosed risks relating to litigation, it did not disclose specific risk relating to potential litigation arising from adverse findings on the efficacy of phenylephrine.

What can Investors Do: Shareholders who incurred losses during the class period, have until December 8, 2023, to move the court to become a lead plaintiff in this action. A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231021335509/en/

Contacts

Johnson Fistel, LLP

James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471

jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

More News

View More
Prediction Markets Are Coming: Can DraftKings & FanDuel Survive?
Today 14:04 EST
Via MarketBeat
Tickers DKNG FLUT HOOD
Shopify Pullback Sets Stage for 20% Rally to $200 Target
Today 12:57 EST
Via MarketBeat
Tickers GOOGL NVDA SHOP
Roku's Profit Engine Roars to Life: Is the Rally Just Beginning?
Today 11:23 EST
Via MarketBeat
Tickers AMZN GOOGL ROKU
Why Palantir Stock Fell After Another Strong Quarter
Today 11:14 EST
Via MarketBeat
Tickers NVDA PLTR
Intel's SambaNova Play Isn't an Acquisition, It's an Ambush
Today 10:31 EST
Via MarketBeat
Tickers INTC

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.84
-4.16 (-1.64%)
AAPL  270.56
+1.51 (0.56%)
AMD  253.53
-6.12 (-2.36%)
BAC  53.45
-0.11 (-0.20%)
GOOG  278.76
-5.36 (-1.89%)
META  631.72
-5.99 (-0.94%)
MSFT  512.91
-4.12 (-0.80%)
NVDA  200.34
-6.54 (-3.16%)
ORCL  248.82
-9.03 (-3.50%)
TSLA  450.32
-18.05 (-3.85%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap